83 related articles for article (PubMed ID: 24850877)
1. Correlations between changes in cytokines and clinical outcomes for early phase (proof of concept) trials in active diffuse systemic sclerosis using data from an imatinib study.
Pope J; Walker KM; de Leon F; Vanderhoek L; Seney S; Summers KL
Rheumatology (Oxford); 2014 Oct; 53(10):1830-4. PubMed ID: 24850877
[TBL] [Abstract][Full Text] [Related]
2. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.
Pope J; McBain D; Petrlich L; Watson S; Vanderhoek L; de Leon F; Seney S; Summers K
Arthritis Rheum; 2011 Nov; 63(11):3547-51. PubMed ID: 21769850
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.
Prey S; Ezzedine K; Doussau A; Grandoulier AS; Barcat D; Chatelus E; Diot E; Durant C; Hachulla E; de Korwin-Krokowski JD; Kostrzewa E; Quemeneur T; Paul C; Schaeverbeke T; Seneschal J; Solanilla A; Sparsa A; Bouchet S; Lepreux S; Mahon FX; Chene G; Taïeb A
Br J Dermatol; 2012 Nov; 167(5):1138-44. PubMed ID: 23039171
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial.
Spiera RF; Gordon JK; Mersten JN; Magro CM; Mehta M; Wildman HF; Kloiber S; Kirou KA; Lyman S; Crow MK
Ann Rheum Dis; 2011 Jun; 70(6):1003-9. PubMed ID: 21398330
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial.
Gordon J; Udeh U; Doobay K; Magro C; Wildman H; Davids M; Mersten JN; Huang WT; Lyman S; Crow MK; Spiera RF
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-189-93. PubMed ID: 25152211
[TBL] [Abstract][Full Text] [Related]
6. Molecular framework for response to imatinib mesylate in systemic sclerosis.
Chung L; Fiorentino DF; Benbarak MJ; Adler AS; Mariano MM; Paniagua RT; Milano A; Connolly MK; Ratiner BD; Wiskocil RL; Whitfield ML; Chang HY; Robinson WH
Arthritis Rheum; 2009 Feb; 60(2):584-91. PubMed ID: 19180499
[TBL] [Abstract][Full Text] [Related]
7. Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment.
Haddon DJ; Wand HE; Jarrell JA; Spiera RF; Utz PJ; Gordon JK; Chung LS
J Rheumatol; 2017 May; 44(5):631-638. PubMed ID: 28298564
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibitor therapy for systemic sclerosis: Quo Vadis?
Mendoza FA; Jiménez SA
Arthritis Rheum; 2011 Nov; 63(11):3199-203. PubMed ID: 21769846
[No Abstract] [Full Text] [Related]
9. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease.
Khanna D; Saggar R; Mayes MD; Abtin F; Clements PJ; Maranian P; Assassi S; Saggar R; Singh RR; Furst DE
Arthritis Rheum; 2011 Nov; 63(11):3540-6. PubMed ID: 21769849
[TBL] [Abstract][Full Text] [Related]
10. Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis.
Divekar AA; Khanna D; Abtin F; Maranian P; Saggar R; Saggar R; Furst DE; Singh RR
Clin Immunol; 2011 Dec; 141(3):293-303. PubMed ID: 22015344
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases.
Tamaki Z; Asano Y; Hatano M; Yao A; Kawashima T; Tomita M; Kinugawa K; Nagai R; Sato S
Mod Rheumatol; 2012 Feb; 22(1):94-9. PubMed ID: 21633912
[TBL] [Abstract][Full Text] [Related]
12. [A new therapeutic avenue for severe systemic sclerosis: imatinib mesylate].
Taïeb A; Constans J; Mahon FX
Rev Med Interne; 2008 Mar; 29(3):173-5. PubMed ID: 17597261
[No Abstract] [Full Text] [Related]
13. Imatinib for the treatment of refractory, diffuse systemic sclerosis.
Sfikakis PP; Gorgoulis VG; Katsiari CG; Evangelou K; Kostopoulos C; Black CM
Rheumatology (Oxford); 2008 May; 47(5):735-7. PubMed ID: 18326532
[No Abstract] [Full Text] [Related]
14. Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib.
Bournia VK; Evangelou K; Sfikakis PP
Semin Arthritis Rheum; 2013 Feb; 42(4):377-90. PubMed ID: 22789835
[TBL] [Abstract][Full Text] [Related]
15. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma.
Sultan N; Pope JE; Clements PJ;
Rheumatology (Oxford); 2004 Apr; 43(4):472-8. PubMed ID: 14679295
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials.
Iwamoto N; Distler JH; Distler O
Curr Rheumatol Rep; 2011 Feb; 13(1):21-7. PubMed ID: 21042889
[TBL] [Abstract][Full Text] [Related]
17. High reactive oxygen species in fibrotic and nonfibrotic skin of patients with diffuse cutaneous systemic sclerosis.
Bourji K; Meyer A; Chatelus E; Pincemail J; Pigatto E; Defraigne JO; Singh F; Charlier C; Geny B; Gottenberg JE; Punzi L; Cozzi F; Sibilia J
Free Radic Biol Med; 2015 Oct; 87():282-9. PubMed ID: 26143738
[TBL] [Abstract][Full Text] [Related]
18. The relationship between vascular biomarkers and disease characteristics in systemic sclerosis: elevated MCP-1 is predominantly associated with fibrotic manifestations.
Yalçinkaya Y; Çinar S; Artim-Esen B; Kamali S; Öcal L; Deniz G; Inanç M
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):110-114. PubMed ID: 27749243
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]